
|Podcasts|December 3, 2021
Pharmacy Focus: Psychedelic Pharmacy - Episode 2
Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research.
Advertisement
In the second episode of the Psychedelic Pharmacy series, Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research. In the interview, Nyquvest said he believes psychedelics will lead to a major shift in the mental health treatment paradigm in the next 3 to 5 years.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
3
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
4
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
5






































































































